Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808688 · ClinicalTrials.gov registry record · Phase 4
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
A Phase 4 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 261
- Enrollment target
NCT03808688 is a Phase 4 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 261 participants.
The verdict
NCT03808688, a Phase 4 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 261 participants
- Enrollment target
Study Summary
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.
Interventions
- DRUG Netarsudil Ophthalmic Solution 0.02%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2019-07-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808688
The ClinicalTrials.gov registry entry for NCT03808688 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Netarsudil Ophthalmic Solution 0.02% is the first listed.
NCT03808688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03808688 about?
NCT03808688 is a clinical study titled "Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting". To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-labe...
What is the current status of trial NCT03808688?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 261 participants. The study started on 2018-12-27. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT03808688?
The interventions under investigation include: Netarsudil Ophthalmic Solution 0.02% (DRUG).
Who is sponsoring clinical trial NCT03808688?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.